The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Treating high-risk colon cancer when mFOLFIRINOX intensification fails
Jaafar Bennouna, MD, Foch Hospital, Suresnes, France, advocates for a shift from adjuvant to neoadjuvant treatment strategies, even in microsatellite-stable (MSS) colon cancer, noting that while immunotherapy is established in microsatellite-instable (MSI) disease, the efficacy of neoadjuvant approaches in MSS tumors remains an open question. Emerging treatment modalities including cancer vaccines, antibody-drug conjugates (ADCs), and bispecific antibodies as potential components of neoadjuvant strategies to improve outcomes in this patient population. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
